Advances in biomarkers for the early diagnosis of prostate cancer / 癌症
Chinese Journal of Cancer
;
(12): 229-233, 2010.
Article
in English
| WPRIM
| ID: wpr-292604
ABSTRACT
More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for early diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of PCa, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives, HPC1, PCA3, TMPRSS2 ETS, GSTP1, AMACR, GOLPH2, EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the early diagnosis and the prognostic monitoring of patients with PCa.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Neoplasms
/
Sarcosine
/
Biomarkers, Tumor
/
Oncogene Proteins, Fusion
/
Prostate-Specific Antigen
/
Racemases and Epimerases
/
Early Diagnosis
/
Diagnosis
/
Endoribonucleases
/
Glutathione S-Transferase pi
Type of study:
Diagnostic study
/
Screening study
Limits:
Humans
/
Male
Language:
English
Journal:
Chinese Journal of Cancer
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS